Search results for " Adjuvant"

showing 10 items of 245 documents

Novel Approaches for Glioblastoma Treatment: Focus on Tumor Heterogeneity, Treatment Resistance, and Computational Tools

2019

BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide (TMZ), a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterog…

Cancer Researchmedicine.medical_treatmentDNA Mutational AnalysisBrain tumorBioinformaticsComplete resectionTumor heterogeneityCancer VaccinesMicrotubulesArticleClonal EvolutionMachine LearningGenetic HeterogeneityCancer stem cellAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineHumansTreatment resistancePrecision MedicineDNA Modification MethylasesImmune Checkpoint InhibitorsTemozolomideModels Geneticbusiness.industryBrain NeoplasmsTumor Suppressor ProteinsBrainComputational BiologyChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadiation therapyDNA Repair EnzymesOncologyDrug Resistance NeoplasmMutationTumor Suppressor Protein p53businessGlioblastomaGlioblastomamedicine.drug
researchProduct

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…

2018

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…

OncologyReceptor ErbB-2Settore MED/06 - Oncologia Medicaletrozolelaw.inventionAdjuvant anastrozolechemistry.chemical_compound0302 clinical medicineRandomized controlled trialExemestanelawAdjuvant anastrozole; exemestane; letrozole; tamoxifen; breast cancerAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicinetamoxifenAromatase InhibitorsLetrozoleHazard ratioMiddle AgedReceptors EstrogenTolerabilityOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleReceptors ProgesteroneBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtySocio-culturaleAnastrozoleBreast NeoplasmsAnastrozoleDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineAromatase InhibitorHumansAgedAntineoplastic Combined Chemotherapy ProtocolAndrostadienebusiness.industrymedicine.diseaseAndrostadieneschemistrybusinessexemestaneTamoxifen
researchProduct

Uncommon Synchronous Association between Ovarian Carcinoma and Gastrointestinal Stromal Tumor: A Case Study and Literature Review

2013

Background The association of gastrointestinal stromal tumors (GIST) and other cancers is well known, but its synchronous occurrence with gynecological malignancies is very uncommon. Usually, the diagnosis is accidentally established. We describe a patient with GIST and concurrent ovarian cancer and discuss the clinical implications of this finding. Case report A 64-year-old woman with a prior diagnosis of ovarian cancer developed a second recurrence after having undergone two operations and adjuvant chemotherapy. While tumor debulking was performed, a small, nonsuspicious lesion was removed from the greater curvature of the stomach. Histology revealed a GIST. Conclusion The association of …

Cancer ResearchPaclitaxelGastrointestinal Stromal TumorsOvariectomyAntigens CD34Carcinoma Ovarian EpithelialCystectomyHysterectomyCarboplatin030218 nuclear medicine & medical imagingNeoplasms Multiple PrimarySalpingectomy03 medical and health sciencesPancreatectomy0302 clinical medicineOvarian cancerSynchronous occurrenceStomach NeoplasmGastrectomyStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastrointestinal Stromal TumorBiomarkers TumorHumansNeoplasms Glandular and EpithelialColectomyOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmGeneral MedicineMiddle AgedImmunohistochemistryProto-Oncogene Proteins c-kitTreatment OutcomeOncologyChemotherapy AdjuvantCA-125 Antigen030220 oncology & carcinogenesisSplenectomyLymph Node ExcisionFemaleHumanTumori Journal
researchProduct

Relationship Between Thymidylate Synthase and p53 and Response to FEC Versus Taxane Adjuvant Chemotherapy for Breast Carcinoma

2011

Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients wit…

Bridged-Ring CompoundsOncologymedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentBreast NeoplasmsThymidylate synthaseBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineAdjuvant therapyHumansPharmacology (medical)CyclophosphamideEpirubicinNeoplasm StagingPharmacologyChemotherapyTaxanebiologybusiness.industryThymidylate SynthasePrognosismedicine.diseaseImmunohistochemistryInfectious DiseasesOncologyChemotherapy AdjuvantFluorouracilbiology.proteinCancer researchFemaleTaxoidsFluorouracilTumor Suppressor Protein p53businessmedicine.drugEpirubicinJournal of Chemotherapy
researchProduct

Multifocal Biliary Cystadenocarcinoma of the Liver: CT and Pathological Findings

2006

Biliary cystadenocarcinoma is a rare tumor that originates from the hepatobiliary epithelium. Although this tumor can affect any portion of the biliary tree, intrahepatic location is more common. It is usually a slow growing tumor and often asymptomatic until it reaches a considerable size. The lesion is most often solitary and large when discovered; multiple lesions or metastases within the liver are very rare. A 63-year-old man was referred to our institute for weight loss, abdominal discomfort, worsening bulky symptoms in the right upper abdominal quadrant, and an increase in serum aminotransferases that had been present for several months. Spiral CT of the abdomen demonstrated two lesi…

MaleCancer ResearchPathologymedicine.medical_specialtyBiliary CystadenocarcinomaBiopsyCystadenocarcinoma030218 nuclear medicine & medical imagingLiver ct03 medical and health sciences0302 clinical medicineHumansMedicineCystadenocarcinomaTransaminasesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseEpitheliumBiliary Tract Surgical ProceduresRare tumorBiliary Tract Neoplasmsmedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisLaparoscopyRadiologybusinessTomography Spiral ComputedTumori Journal
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis

2004

Background: The benefit of neoadjuvant chemoradiotherapy in oesophageal cancer has been extensively studied but data on survival are still equivocal. Objective: To assess the effectiveness of chemoradiotherapy followed by surgery in the reduction of mortality in patients with resectable oesophageal cancer. Methods: Computerised bibliographic searches of MEDLINE and CANCERLIT (1970–2002) were supplemented with hand searches of reference lists. Study selection: Studies were included if they were randomised controlled trials (RCTs) comparing preoperative chemoradiotherapy plus surgery with surgery alone, and if they included patients with resectable histologically proven oesophageal cancer wit…

medicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentlaw.inventionPostoperative ComplicationsRandomized controlled triallawChemotherapyHumansMedicineEsophageal NeoplasmAdjuvantRandomized Controlled Trials as TopicIntention-to-treat analysisRadiotherapybusiness.industryMortality rateGastroenterologyCancerOdds ratiomedicine.diseaseChemotherapy Adjuvant; Esophageal Neoplasms; Esophagectomy; Humans; Postoperative Complications; Radiotherapy Adjuvant; Randomized Controlled Trials; Survival Analysis; Treatment OutcomeSurvival AnalysisSurgeryEsophagectomyRadiation therapyOesophagusTreatment OutcomeChemotherapy AdjuvantEsophagectomyRandomized Controlled TrialChemotherapy; Adjuvant; Esophageal Neoplasms; Esophagectomy; Humans; Postoperative Complications; Radiotherapy; Randomized Controlled Trials as Topic; Survival Analysis; Treatment OutcomeRadiotherapy AdjuvantPostoperative ComplicationSurvival AnalysibusinessChemoradiotherapyHumanGut
researchProduct

A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman.

2019

Background/aim Pineoblastoma of the adult age is an uncommon tumor with only 200 cases reported. A standardized approach for an optimal adjuvant strategy is currently lacking. The case presented herein also deals with the issue of central nervous system tumors in pregnancy. Case report A 21-year-old pregnant woman presented with massive hydrocephalus due to a mass in the pineal region detected with MRI. After positioning an urgent ventricular derivation, a cesarean section was performed. During a third ventriculocisternostomy, a biopsy revealed a pineoblastoma. After a maximal safe resection, postoperative craniospinal irradiation for a total dose of 36 Gy plus a sequential boost to the tum…

AdultCancer Researchmedicine.medical_specialtyVincristinePineal GlandCraniospinal IrradiationVentriculostomy03 medical and health sciences0302 clinical medicinePregnancyBiopsyMedicineHumansPineoblastomaPregnancymedicine.diagnostic_testbusiness.industryCesarean SectionGestational ageGeneral MedicineChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingHydrocephalusAdult PineoblastomaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologybusinessPinealomaPregnancy Complications Neoplasticmedicine.drugAnticancer research
researchProduct

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled super…

2014

Summary Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival. We report updated results from our primary analysis to establish the long-term benefit of trastuzumab-containing neoadjuvant therapy. Methods We did this multicentre, open-label, randomised trial in women with HER2-positive locally advanced or inflammatory breast cancer. Participants were randomly assigned (1:1), by computer program with a minimisation technique, to receive neoadjuvant chemotherapy alone or with …

OncologyAdultmedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsKaplan-Meier EstimateAntibodies Monoclonal HumanizedInflammatory breast cancerDisease-Free Survivallaw.inventionBreast cancerRandomized controlled triallawTrastuzumabInternal medicinemedicineClinical endpointHumansskin and connective tissue diseasesneoplasmsNeoadjuvant therapyAgedProportional Hazards Modelsbusiness.industryHazard ratioGenes erbB-2Middle AgedTrastuzumabmedicine.diseaseNeoadjuvant TherapyClinical trialTreatment OutcomeOncologyChemotherapy AdjuvantFemaleInflammatory Breast Neoplasmsbusinessmedicine.drugFollow-Up StudiesThe Lancet. Oncology
researchProduct

Mycophenolate is effective in the treatment of pemphigus vulgaris.

1999

Background Pemphigus vulgaris is a potentially life-threatening autoimmune disease. Although combination therapies with prednisone and azathioprine are usually effective in controlling the disease, some patients either do not respond to this treatment or show early relapses. Objective To find out whether mycophenolate mofetil would be an effective drug in controlling pemphigus vulgaris in patients who failed initial treatment with azathioprine and prednisone. Results Twelve patients who were initially diagnosed as having pemphigus vulgaris and had relapsed while undergoing treatment with azathioprine (1.5-2 mg/kg of body weight) and prednisolone (2 mg/kg of body weight) subsequently receive…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentPrednisoloneAzathioprineDermatologyMycophenolic acidPrednisoneAzathioprineMedicineHumansChemotherapybusiness.industryPemphigus vulgarisGeneral MedicineMiddle AgedMycophenolic Acidmedicine.diseaseDermatologyPemphigusTreatment OutcomeChemotherapy AdjuvantPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsPemphigusmedicine.drugArchives of dermatology
researchProduct